Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Predictors of survival with and without allogeneic stem cell transplantation after first salvage therapy with blinatumomab and/or inotuzumab ozogamicin for Relapsed/Refractory B-cell acute lymphoblastic leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

NJNitin JainFHFadi HaddadESElizabeth J. Shpall

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows impact of early relapse and MRD on survival in B-ALL patients post-salvage therapy, highlighting allo-HSCT benefits.

Key Points

  • Overall, 4-year overall survival was 46% for B-ALL patients treated with blinatumomab and inotuzumab ozogamicin after first salvage therapy.
  • MRD positivity after salvage therapy significantly worsened overall survival, with a hazard ratio of 2.4.
  • This analysis evaluated adults with R/R B-ALL receiving either blinatumomab, inotuzumab ozogamicin, or both as first salvage treatment.
  • Late relapse or achieving MRD negativity may lead to better outcomes without the need for stem cell transplantation.

Cite This Study

Jain et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc78https://doi.org/10.1182/blood-2025-549
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Predictors of survival in adults with B-cell acute lymphoblastic leukemia treated with blinatumomab and/or inotuzumab ozogamicin in first salvage2026
  2. 2Selecting the optimal bridging therapy for B-ALL: A multicenter comparison of blinatumomab, inotuzumab ozogamicin, and CAR-T prior to allo-HSCT2025
  3. 3Optimal therapy for pediatric B-ALL in first relapse: Comparative effectiveness of blinatumomab to hematopoietic cell transplantation versus CD19 CAR T cell therapy2025
  4. 4The addition of inotuzumab ozogamicin to frontline hyper-CVAD and sequential blinatumomab leads to durable survival outcomes in adults with newly diagnosed B-cell acute lymphoblastic leukemia: Four-year follow-up of a phase 2 study2025 · 2 citations
  5. 5Revisiting the role of second allogeneic HCT for post-transplant relapse in acute lymphoblastic leukemia: Comparative outcomes in the era of targeted therapies2025